Stockreport

Ultragenyx gains Breakthrough Therapy status for setrusumab for genetic disorder Oct. 07, 2024 2:27 PM ET By: Jonathan Block , SA News Editor [Seeking Alpha]

Ultragenyx Pharmaceutical Inc.  (RARE) 
Last ultragenyx pharmaceutical inc. earnings: 2/13 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.ultragenyx.com/investor-relations
PDF ) setrusumab for osteogenesis imperfecta, a group of rare genetic disorders impacting bone metabolism. Ultragenyx (RARE) said the status was granted based on data f [Read more]